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SUMMARY
Salmonella Hadar ranks in the top ten serovars reported from humans in Switzerland. In this
study, all 64 S. Hadar strains isolated from different patients from 2005 to 2010 in Switzerland
were characterized by (i) assessing phenotypic antimicrobial resistance proﬁles using the disk
diffusion method and (ii) by genotyping using pulsed-ﬁeld gel electrophoresis (PFGE) in order to
evaluate the relationship of the strains. The annual incidences varied between 0·32/100000 in
2005 (highest incidence) and 0·065/100000 in 2007 (lowest incidence). In total 71·8% of the
isolates were resistant to nalidixic acid. Although 40·6% of the strains were resistant to the
β-lactam antibiotic ampicillin, they remained susceptible to the third-generation cephalosporin
cefotaxime. Genotyping revealed a primary cluster consisting of 42 strains, sharing a similarity
of >92%, with a subcluster of 18 strains with indistinguishable patterns. Resistance proﬁles
allowed further differentiation within this subcluster providing a link of two strains to an
outbreak in Spain.
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INTRODUCTION
Non-typhoidal Salmonella are commonly acquired
from contaminated food and are an important cause
of gastroenteritis and bacteraemia, posing a world-
wide threat to public health [1, 2]. It is estimated that
Salmonella causes 93·8 million human infections and
155000 deaths annually worldwide [3]. Although
more than 2500 serovars have been identiﬁed,
S. Enteritidis and S. Typhimurium are responsible for
the majority of reported cases of salmonellosis. For
Europe, the distribution of other Salmonella serovars
is reported to vary widely geographically and over
time [4].
S. Hadar ranks in the top ten serovars isolated from
humans in Switzerland over recent years and has been
reported to be associated with poultry [5]. This serovar
has been responsible for several foodborne outbreaks,
e.g. in Italy in 1994 [6] and 2000 [7], and in Spain in
2005 [8].
As with other non-typhoidal Salmonella, infections
due to S. Hadar often manifest themselves as self-
limiting gastroenteritis, but severe invasive infections
can also occur which require antimicrobial treatment.
Drugs for Salmonella infection include ﬂuoroquino-
lones, trimethoprim-sulfamethoxazole, ampicillin, or
third-generation cephalosporins [9]. The emergence
and spread of resistant bacteria and subsequent failure
of treatment of infections is a signiﬁcant and increas-
ing global public health problem [10]. Resistance to
antimicrobials used to treat invasive Salmonella is
also increasing, including extended spectrum cepha-
losporins and quinolones [11]. S. Hadar is reported
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less frequently compared to other serovars; nonethe-
less, these isolates have been described as a reservoir
of antimicrobial resistance [12].
In this study, all 64 S. Hadar strains isolated from
different patients from 2005 to 2010 in Switzerland
were further characterized by (i) assessing phenotypic
antimicrobial resistance proﬁles using the disk diffusion
method and (ii) by genotyping using pulsed-ﬁeld gel
electrophoresis (PFGE) after macrorestriction with
XbaI in order to evaluate the relationship of the strains.
METHODS
Strains
Human salmonellosis is a notiﬁable disease in
Switzerland and isolates have to be submitted to the
National Centre for Enteropathogenic Bacteria
(NENT). NENT, in cooperation with the Swiss
Federal Ofﬁce of Public Health, collects clinical data
and conducts ﬁnal serological identiﬁcation by slide
agglutination with commercial antisera according to
the Kauffmann–White scheme [13]. From 2005 to
2010, 10048 cases of Salmonella infection were
reported to the Swiss Federal Ofﬁce of Public
Health [14]. During this period, 64 human isolates
of S. Hadar were collected and selected for this
study. Multiple isolates from the same patient were
excluded, isolates from individual family members
were regarded as distinct isolates. All samples were
collected and submitted by diagnostic laboratories,
hospitals or family doctors throughout Switzerland.
Antimicrobial susceptibility testing
The strains were tested for antimicrobial resistance
by the disk diffusion method according to the
Clinical and Laboratory Standards Institute [15].
The panel of antibiotic disks (Becton, Dickinson and
Company, USA) consisted of ampicillin (AM10),
amoxicillin/clavulanic acid (AMC30), cephalothin
(CF30), cefotaxime (CTX30), ciproﬂoxacin (CIP5),
gentamycin (GM10), tetracycline (Te30), streptomy-
cin (S10), chloramphenicol (C30), kanamycin (K30),
nalidixic acid (NA30), sulfamethoxazole (SMZ), and
trimethoprim (TMP5). The strains were classiﬁed as
resistant, intermediate or susceptible to each antimi-
crobial agent according to CLSI criteria [15]. For
calculations of percentages, intermediate susceptibility
was considered as resistant. Strains displaying resist-
ance to three or more antimicrobial compounds of
different classes were deﬁned as multidrug resistant.
Genotyping
PFGE was performed by following the CDC PulseNet
protocol (http://www.cdc.gov/pulsenet/protocols.htm)
with minor modiﬁcations. In brief, strains were
grown on blood agar at 37 °C overnight. Colonies
from blood agar were re-suspended in cell suspension
buffer (OD600=1). The bacterial cell suspension was
mixed with 400 μl of 1·4% pulsed-ﬁeld certiﬁed agarose
(Bio-Rad, Germany) and cells were lysed by proteinase
K treatment (0·1 mg/ml at 55 °C) overnight. After lysis
the plugs were washed twice for 30 min in ultrapure
water and four times for 1 h in 0·5×Tris-EDTA (TE)
buffer. After washing with TE buffer, DNA agarose
plugs were incubated overnight in the presence of
XbaI (Roche, Germany) according to the manufac-
turer’s instructions. Restricted DNA in plug slices
was separated in a 1% SeaKem Gold (BioConcept,
Switzerland) agarose gel at 6 V/cm in 0·5×Tris-
borate-EDTA buffer cooled to 12 °C in a CHEF-DR
III system (Bio-Rad). The pulse times were ramped
from 2 s to 64 s for 20 h at an angle of 120°. Gels were
stained with ethidium bromide and visualized under
UV light transillumination with Gel Doc (Bio-Rad)
and analysed with BioNumerics software (Applied
Maths, Belgium). Pairwise similarities between the
XbaI pulsed-ﬁeld patterns were calculated using the
DICE similarity coefﬁcient. Clustering was based on
the unweighted pair-group method with averages
(UPGMA), setting tolerance and optimization each at
1·5%. S. Braenderup strain H9812 (ATCC BAA 664)
was used as a reference strain.
RESULTS
Clinical and epidemiological data
Sixty-one (95%) S. Hadar strains were isolated from
stool samples. Of the remaining strains, one originated
from a blood sample, one from urine and one isolate
was of unknown origin.
During the whole study period S. Hadar was
ranked in the top ten serovars reported from humans
in Switzerland. Of the total annual Salmonella iso-
lates, this serovar accounted for 1·3% in 2005, 0·6%
in 2006, 0·3% in 2007, 0·4% in 2008, 0·8% in 2009
and 0·5% in 2010. The annual incidence of S. Hadar
was highest in 2005 with a value of 0·32/100000. In
2006 the annual incidence was 0·13/100000, followed
by the lowest incidence of 0·065/100000 in 2007, 0·1/
100000 in 2008, 0·14/100000 in 2009 and ﬁnally,
0·076/100000 in 2010.
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Age was known for 62 of the 64 patients (Fig. 1). In
the 45 years age group, eight strains were identiﬁed
accounting for 12·5% of the study collection. In the
6–14 years age group, four (6·3%) strains were
found. The majority of 47 (73·4%) cases was found
in the 15–65 years age group; 7·8% of the strains orig-
inated from people aged >65 years (ﬁve strains).
Of all patients, only three had a documented history
of foreign travel. One patient aged >65 years had visi-
ted Kenya. Two patients were infants in the <5 years
age group; one had been to Macedonia and the other
to Egypt. Two patients were members of the same
family and both were in the 15–65 years age group.
Antimicrobial susceptibility
A total of 28 (43·8%) strains were resistant and 30
(46·9%) strains revealed multidrug resistance
(Fig. 1). Only six (9·4%) strains showed full suscepti-
bility to all antimicrobials.
Resistance rates were high for the quinolone nali-
dixic acid (71·8%). Only two strains were resistant to
ciproﬂoxacin. The frequency for resistance to tetra-
cycline was 70·3%. For the class of aminogylcosides,
resistance to streptomycin was detected in 75% of
the strains. All strains were fully susceptible to genta-
mycin and three (4·7%) strains were resistant to
kanamycin.
A high percentage (40·6%) of the strains were resist-
ant to the β-lactam antibiotic ampicillin and 29·7%
revealed resistance to the ﬁrst-generation cephalos-
porin cephalothin. Four isolates were resistant (inter-
mediate) to the combination of amoxicillin with the
β-lactamase inhibitor clavulanic acid and all strains
were fully susceptible to the third-generation cephalos-
porin cefotaxime. Combined resistance to ampicillin
and nalidixic acid was exhibited by 24 strains
(37·5%). We found 21 sulfamethoxazole- and three
trimethoprim-resistant strains, which amounted to
32·8% and 4·7%, respectively. Three strains were
resistant to both antimicrobials. All isolates except
two (3·1%) were susceptible to chloramphenicol.
From 2005 to 2010 no major shift in resistance
patterns was observed. However, resistance rates
were maintained at high levels. In different years
80–100% of the isolated strains were resistant to at
least one antimicrobial.
Genetic relationship of Swiss S. Hadar isolates
PFGE analysis with the XbaI restriction enzyme
revealed 34 banding patterns in the 64 isolates
(Fig. 2). In general, PFGE analysis of the different
strains showed a close clonal relationship. One pri-
mary cluster was observed, consisting of 42 strains
sharing a similarity of >92%. Within this cluster 18
strains shared a similarity of 100%. Eight of these
indistinguishable strains were isolated in 2005, which
amounted to 33·3% of the 24 isolates collected in
2005. In the following years, this pulsotype appeared
less frequently (in 2006 two strains were detected, in
2007 there was one strain, in 2008 we found three,
in 2009 there were four, and in 2010 one strain was
found). Except for strains N05-1373 and N05-1374,
which originated from two individuals from the
same family, no connection between the patients
could be established. Samples had been obtained
and submitted to NENT from all over Switzerland.
Age groups and gender were distributed evenly and
all strains originated from stool samples.
Two of these 18 strains (N05-1374, N06-1737)
showed the resistance pattern AM-CF-S-NA-TE;
four strains (N05-216, N05-1556, N05-1957, N09-
1491) showed the resistance pattern AM-CF-S-
NA-TE-SMZ and the rest of these 18 strains were
heterogeneous in regard to their resistances.
DISCUSSION
On average, the annual incidence of salmonellosis
in Switzerland for 2005–2010 was 21·78/100000 [14].
From this period, isolates from 64 cases of human
infections with S. Hadar were selected and screened
for antibiotic resistance and for genetic relationship.
Strains were from medical institutions from all over
Switzerland.
In an analysis of the global distribution of the
15 most frequently identiﬁed serovars of Salmonella
isolated from humans, S. Hadar was found in a pro-
portion of 1·5% in Europe [16]. In Switzerland,
S. Hadar ranked in the top ten serovars reported
from humans during to whole study period.
Although salmonellosis is a notiﬁable disease, it is
normally self-limiting in otherwise healthy individuals
and hence many infections go undetected by the
authorities, accounting for an unknown number of
unreported cases. It has been suggested that reported
laboratory-conﬁrmed Salmonella incidences should
be adjusted for under-ascertainment using multipliers
ranging from 3·2 to 14·3 for European countries and
as high as 38 for the USA [3]. Consequently, it must
be assumed that the true population burden of disease
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Fig. 1. Resistance proﬁles and anamnestic data of the 64 S. Hadar strains. Strains resistant, intermediate or susceptible to
a speciﬁc antibiotic are highlighted in grey, light grey, or white, respectively. AM, ampicillin; AMC, amoxicillin-clavulanic
acid; CF, cephalothin; CTX, cefotaxime; GM, gentamicin; K, kanamycin; S, streptomycin; TE, tetracycline; CIP,
ciproﬂoxacin; NA, nalidixic acid; SMZ, sulfamethoxazole; TMP, trimethoprim; C, chloramphenicol; m, male; f, female;
nd, no data.
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caused by S. Hadar is greater than that suggested by
our ﬁndings.
We found that the majority of strains were resistant
to nalidixic acid, tetracycline and β-lactam antibiotics,
excluding third-generation cephalosporins. The emerg-
ence and spread of multidrug resistance in patho-
genic as well as commensal bacteria in general and
in Salmonella spp. in particular is an increasing global
concern [10, 17, 18]. Dissemination of resistance genes
through bacterial populations needs to be monitored
globally as well as locally [19]. Moreover, there is evi-
dence that less frequent serovars, such as S. Hadar,
are reservoirs of antibiotic resistance genes [12]. The
considerable percentage (46·9%) of multidrug-
resistant strains in our strain collection is in accord
with the results of a European multi-centre study,
which describes 37% multidrug-resistant Salmonella
isolates [20].
Reisistance to nalidixic acid in salmonellae is
of great concern, as it has been reported to be an indi-
cator for reduced susceptibility to the drug of choice,
ciproﬂoxacin, resulting in possible treatment failure
[21–23]. Consequently, the 71·8% nalidixic acid-
resistant S. Hadar of this study must be considered
as having reduced susceptibility to ciproﬂoxacin, and
thus potentially treatment-resistant. Interestingly, the
strain that was isolated from blood, and presumably
associated with invasive infection, was susceptible to
both nalidixic acid and ciproﬂoxacin.
Reports on the emergence of extended-spectrum
β-lactamase (ESBL)-resistant salmonellae give rise to
concern [24]. Genes encoding for ESBLs, predomi-
nantly blaTEM, blaSHV and blaCTX variants have
been detected in various Salmonella serovars isolated
from humans as well as from poultry and poultry pro-
ducts [25]. However, all the S. Hadar isolates in this
study were susceptible to cefotaxime. So far, resistance
to ESBL antibiotics is not yet an issue in S. Hadar iso-
lates in Switzerland. Nevertheless, continued surveil-
lance for the presence of ESBL in Salmonella spp. is
needed in order to minimize the risks to future treat-
ment [26].
PFGE analysis showed a close clonal relationship
for this serovar, similar to what is also known for
S. Enteritidis. In the primary cluster, consisting of
42 strains sharing a similarity of >92%, a subcluster
of 18 strains with indistinguishable patterns was
observed. By combining the PFGE and the resistance
patterns of these strains, two strains (N05-1374,
N06-1737) isolated in 2005 and early 2006 are indis-
tinguishable from a S. Hadar strain responsible for a
chicken meat-borne outbreak in Spain [8], suggesting
a possible exposure of these patients in Spain.
ACKNOWLEDGEMENTS
We thank Grethe Sägesser for her help in strain collec-
tion and technical support and the Swiss Federal
Fig. 2. Pulsed-ﬁeld gel electrophoresis (PFGE) patterns of the 64 S. Hadar strains. The primary PFGE cluster (92%
similarity) is indicated by light grey.
88 N. Cernela and others
https:/www.cambridge.org/core/terms. https://doi.org/10.1017/S095026881300054X
Downloaded from https:/www.cambridge.org/core. University of Basel Library, on 30 May 2017 at 18:41:40, subject to the Cambridge Core terms of use, available at
Ofﬁce of Public Health for ﬁnancial support. We also
thank Silvia Herrera Leon for providing the pattern of
the S. Hadar outbreak strain from 2005 in Spain.
DECLARATION OF INTEREST
None.
REFERENCES
1. Rabsch W, Tschape H, Baumler AJ. Non-typhoidal sal-
monellosis: emerging problems. Microbes and Infection
2001; 3: 237–247.
2. Olsen SJ, et al. The changing epidemiology of sal-
monella: trends in serovars isolated from humans in
the United States, 1987–1997. Journal of Infectious
Disease 2001; 183: 753–761.
3. Majowicz SE, et al. The global burden of nontyphoidal
salmonella gastroenteritis. Clinical Infectious Disease
2010; 50: 882–889.
4. Huehn S, et al. Virulotyping and antimicrobial resist-
ance typing of Salmonella enterica serovars relevant to
human health in Europe. Foodborne Pathogen and
Diseases 2010; 7: 523–535.
5. Anon. European Food Safety Authority (EFSA) (http://
www.efsa.europa.eu/de/scdocs/doc/1533.pdf). Accessed
29 January 2013.
6. Fantasia M, et al. Conventional and molecular
approaches to isolates of Salmonella Hadar from spora-
dic and epidemic cases. Journal of Applied Microbiology
1997; 82: 494–498.
7. Di Giannatale E, et al. Investigation of an outbreak of
Salmonella enterica subsp. enterica serovar Hadar
food illness in the Abruzzi region of Italy. Veterinary
Italian 2008; 44: 405–427.
8. Lenglet A. Over 2000 cases so far in Salmonella Hadar
outbreak in Spain associated with consumption of pre-
cooked chicken, July–August, 2005. Eurosurveillance
2005; 11: 10(8).
9. Hohmann EL. Nontyphoidal salmonellosis. Clinial In-
fectious Disease 2001; 32: 263–269.
10. Anon. World Health Organisation: tackling antibiotic
resistance from a food safety perspective in Europe.
Copenhagen, 2011.
11. Parry CM. Antimicrobial drug resistance in Salmonella
enterica. Current Opinion in Infectious Diseases 2003;
16: 467–472.
12. Bagger-Skjøt L, et al. Less frequent Salmonella serovars
as a reservoir of antimicrobial resistance. Journal of
Antimicrobial Chemotherapy 2007; 59: 814–815.
13. Grimont PAD, Weill FX. Antigenic Formulae of the
Salmonella Serovars, 9th edn. WHO Collaborating
Center for Reference and Research on Salmonella,
Institut Pasteur: Paris, 2007.
14. Anon. Swiss Federal Ofﬁce for Public Health (http://
www.bag.admin.ch/k_m_meldesystem/00733/00813/).
Accessed 29 January 2013.
15. CLSI. Clinical and Laboratory Standards Institute:
Performance Standards for Antimicrobial Susceptibility
Testing; Eighteenth Informational Supplement. CLSI
document M100-S18 2008, Wayne, PA.
16. Hendriksen RS, et al. Global monitoring of salmonella
serovar distribution from the World Health Organiz-
ation global foodborne infections network country
data bank: Results of quality assured laboratories
from 2001 to 2007. Foodborne Pathogens and Diseases
2011; 8: 887–900.
17. van den Bogaard AE, Stobberingh EE. Epidemiology of
resistance to antibiotics. Links between animals and
humans. International Journal of Antimicrobial Agents
2000; 14: 327–335.
18. Threlfall EJ, et al. The emergence and spread of anti-
biotic resistance in food-borne bacteria. International
Journal of Food Microbiology 2000; 62: 1–5.
19. O’Brien TF. The global epidemic nature of antimicro-
bial resistance and the need to monitor and manage it
locally. Clinical Infectious Diseases 1997; 24: 2–8.
20. Threlfall EJ, et al. Antimicrobial drug resistance in iso-
lates of Salmonella enterica from cases of salmonellosis
in humans in Europe in 2000: results of international
multi-centre surveillance. Eurosurveillance 2003; 8: 41–
45.
21. Hakanen A, et al. Detection of decreased ﬂuoroquino-
lone susceptibility in salmonellas and validation of
nalidixic acid screening test. Journal of Clinical Micro-
biology 1999; 37: 3572–3577.
22. Møller Aarestrup F, Wiuff C. Is it time to change
ﬂuoroquinolone breakpoints for Salmonella spp? Anti-
microbial Agents Chemotherapy 2003; 47: 827–829.
23. Crump JA, et al. Reevaluating ﬂuoroquinolone break-
points for Salmonella enterica serovar Typhi and for
non-typhi salmonellae. Clinical Infectious Diseases
2003; 37: 75–81.
24. Coque TM, Baquero F, Canton R. (2008) Increasing
prevalence of ESBL-producing Enterobacteriaceae in
Europe. Eurosurveillance 2008; 20: 13(47).
25. Hasman H, et al. Beta-lactamases among extended-
spectrum beta-lactamase (ESBL)-resistant Salmonella
from poultry, poultry products and human patients in
The Netherlands. Journal of Antimicrobial Chemother-
apy 2005; 56: 115–121.
26. Yates C, Amyes S. Extended-spectrum beta-lactamases
in non-typhoidal Salmonella spp. isolated in the UK
are now a reality: why the late arrival? Journal of Anti-
microbial Chemotherapy 2005; 56: 262–264.
Salmonella Hadar and human infections 89
https:/www.cambridge.org/core/terms. https://doi.org/10.1017/S095026881300054X
Downloaded from https:/www.cambridge.org/core. University of Basel Library, on 30 May 2017 at 18:41:40, subject to the Cambridge Core terms of use, available at
